Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the ''Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Receipt of Approval for Drug Clinical Trial from FDA by a Subsidiary'' published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

22 January 2020

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang and Ms. Mu Haining; and the independent non- executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

Stock code: 600196 Stock abbreviation: Fosun Pharma Annoucement No.: 2020-009

Bond code: 136236 Bond abbreviation: 16Fosun01

Bond code: 143020 Bond abbreviation: 17Fosun01

Bond code: 143422 Bond abbreviation: 18Fosun01

Bond code: 155067 Bond abbreviation: 18Fosun02

Bond code: 155068 Bond abbreviation: 18Fosun03

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Receipt of Approval for Drug Clinical Trial from FDA by a Subsidiary

The board of directors (the "Board") of the Company and all members of the Board warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Fochon Pharmaceuticals, Ltd.* (重慶復創醫藥研究有限公司) ("Fochon Pharma"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company"), has received a letter numbered IND145732 of approval for clinical trial for SAF-189 (namely Furuitini Succinate or the "New Drug") for the treatment of tumors from the FDA (i.e. U.S. Food and Drug Administration). Fochon Pharma intends to conduct clinical trial for the New Drug in the United States upon meeting the conditions shortly.

II. Research Progress of the New Drug

The New Drug is an innovative small molecule chemical drug researched and developed by Fochon Pharma and Shanghai Institute of Materia Medica, Chinese Academy of Sciences mainly for the treatment of tumors. As at the date of this announcement, Furuitini Succinate capsules for the treatment of tumors is in phase I clinical trial in PRC (excluding Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan region).

As at the date of this announcement, drugs with the same target as the New Drug have been marketed in the global market. According to the latest data from IQVIA MIDASTM provided by IQVIA, a global leading provider of professional information and strategic consulting services for the pharmaceutical and healthcare industry, the worldwide sales of the drugs with the same target as the New Drug amounted to approximately US$1,152.68 million in 2018.

Up until December 2019, the cumulative R&D investment of the Group (i.e. the Company and controlling subsidiaries/units) in the New Drug was approximately RMB85.84 million (unaudited) at this stage.

1

III.Risk Warning

Based on our experience in new drug research and development, there are certain risks in new drug development. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

As required by the laws and regulations relating to new drug research and development in the United States, the New Drug is subject to a series of clinical studies and the approval from the drug evaluation authority before it can be marketed.

The research and development and marketing of new drugs are a long-term task involving various uncertainties. Investors are reminded of the investment risks.

Annoucement is hereby given.

Board of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

22 January 2020

* for identification purposes only

2